MannKind (MNKD) News Today $5.00 +0.05 (+1.01%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.97 -0.03 (-0.68%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period MannKind (MNKD) to Release Earnings on ThursdayMannKind (NASDAQ:MNKD) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-mannkind-co-stock/)May 5 at 2:41 AM | marketbeat.comManatuck Hill Partners LLC Acquires 75,000 Shares of MannKind Co. (NASDAQ:MNKD)Manatuck Hill Partners LLC increased its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 300,000 shares of the biopharmaceutical company's stock after buyMay 4 at 6:53 AM | marketbeat.comVoya Investment Management LLC Trims Position in MannKind Co. (NASDAQ:MNKD)Voya Investment Management LLC cut its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 14.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 517,460 shares of the biopharmaceutical company's stock after selling 86,155 shares during the period. Voya IMay 4 at 4:20 AM | marketbeat.comFirst Trust Advisors LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)First Trust Advisors LP acquired a new stake in MannKind Co. (NASDAQ:MNKD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 777,327 shares of the biopharmaceutical company's stock, valued at approximately $4May 4 at 3:44 AM | marketbeat.comApollo Management Holdings L.P. Sells 300,000 Shares of MannKind Co. (NASDAQ:MNKD)Apollo Management Holdings L.P. lowered its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 31.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 664,113 shares of the biopharmaceuticMay 2 at 8:08 AM | marketbeat.comMannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025May 1, 2025 | globenewswire.comRaymond James Financial Inc. Takes Position in MannKind Co. (NASDAQ:MNKD)Raymond James Financial Inc. bought a new stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 654,624 shares of the biopharmaceutical company's stApril 29, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Sold by Nitorum Capital L.P.Nitorum Capital L.P. trimmed its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,747,316 shares of the biopharmaceutical company's stock after selling 410,191 shareApril 28, 2025 | marketbeat.comOberweis Asset Management Inc. Has $6.23 Million Stock Holdings in MannKind Co. (NASDAQ:MNKD)Oberweis Asset Management Inc. raised its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 968,400 shares of the biopharmaceutical company's stock after acquiring an additional 169,600 sApril 27, 2025 | marketbeat.comMariner LLC Buys New Stake in MannKind Co. (NASDAQ:MNKD)Mariner LLC purchased a new position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 263,302 shares of the biopharmaceutical company's stock, valued at appApril 27, 2025 | marketbeat.comInvesco Ltd. Lowers Stock Position in MannKind Co. (NASDAQ:MNKD)Invesco Ltd. lessened its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,220,835 shares of the biopharmaceutical company'sApril 27, 2025 | marketbeat.comMarshall Wace LLP Buys 214,873 Shares of MannKind Co. (NASDAQ:MNKD)Marshall Wace LLP boosted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 30.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 926,683 shares of the biopharmaceutical company's stock after purchasing an additionalApril 26, 2025 | marketbeat.comWalleye Capital LLC Lowers Stock Holdings in MannKind Co. (NASDAQ:MNKD)Walleye Capital LLC lowered its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 91.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,409 shares of the biopharmaceutical company's stock after selling 749,193 shares duApril 26, 2025 | marketbeat.comEversept Partners LP Has $5.86 Million Position in MannKind Co. (NASDAQ:MNKD)Eversept Partners LP reduced its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 54.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 911,025 shares of the biopharApril 24, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 330,100 Shares of MannKind Co. (NASDAQ:MNKD)Renaissance Technologies LLC increased its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 50.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 981,645 shares of the biopharmaceutical company'sApril 21, 2025 | marketbeat.comWells Fargo & Company MN Sells 209,520 Shares of MannKind Co. (NASDAQ:MNKD)Wells Fargo & Company MN trimmed its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 18.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 924,622 shares of the biopharmaceutical company's stock after selling 209,520 shares during theApril 21, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 190,563 Shares of MannKind Co. (NASDAQ:MNKD)Russell Investments Group Ltd. lowered its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 421,659 shares of the biopharmaceutical company's stock afteApril 20, 2025 | marketbeat.comMizuho Upgrades MannKind (NASDAQ:MNKD) to Strong-BuyMizuho raised MannKind to a "strong-buy" rating in a research report on Wednesday.April 13, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. grew its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,058,557 shares of the biopharmacApril 12, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesMannKind Co. (NASDAQ:MNKD - Get Free Report) has been given an average recommendation of "Buy" by the eight research firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommenApril 12, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Gap Down - Should You Sell?MannKind (NASDAQ:MNKD) Shares Gap Down - Time to Sell?April 10, 2025 | marketbeat.comMannKind initiated with an Outperform at MizuhoApril 10, 2025 | markets.businessinsider.comMizuho starts MannKind with Outperform on positive Tyvaso checksApril 10, 2025 | markets.businessinsider.comExodusPoint Capital Management LP Has $2.86 Million Stake in MannKind Co. (NASDAQ:MNKD)ExodusPoint Capital Management LP lifted its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 421.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 444,599 shares of the biopharmaceutical company'sApril 9, 2025 | marketbeat.comPrudential Financial Inc. Lowers Position in MannKind Co. (NASDAQ:MNKD)Prudential Financial Inc. lowered its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 69.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,871 shares of the biopharmaceutical company'April 9, 2025 | marketbeat.comMannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment OptionsApril 7, 2025 | globenewswire.comKLP Kapitalforvaltning AS Buys New Holdings in MannKind Co. (NASDAQ:MNKD)KLP Kapitalforvaltning AS purchased a new position in MannKind Co. (NASDAQ:MNKD - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 53,400 shares of the biopharmaceutical company's stock, valued at approxiApril 7, 2025 | marketbeat.comRBC Capital Sticks to Their Buy Rating for MannKind (MNKD)April 5, 2025 | markets.businessinsider.comMannKind Co. (NASDAQ:MNKD) Shares Acquired by Arrowstreet Capital Limited PartnershipArrowstreet Capital Limited Partnership increased its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 275.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,887,609 shares of the biopharmaceutical company's stocApril 4, 2025 | marketbeat.comHighTower Advisors LLC Sells 96,211 Shares of MannKind Co. (NASDAQ:MNKD)HighTower Advisors LLC lessened its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 67.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,182 shares of the biopharmaceutical companyApril 3, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 654,624 MannKind Co. (NASDAQ:MNKD)Raymond James Financial Inc. purchased a new position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 654,624 shares of the biopharmaceutical company's stock, valued atMarch 27, 2025 | marketbeat.comMannKind management to meet with Cantor FitzgeraldMarch 26, 2025 | markets.businessinsider.comMannKind (MNKD) Gets a Buy from Cantor FitzgeraldMarch 22, 2025 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Rating Increased to Buy at StockNews.comStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday.March 20, 2025 | marketbeat.comVictory Capital Management Inc. Purchases 171,537 Shares of MannKind Co. (NASDAQ:MNKD)Victory Capital Management Inc. increased its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 358.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 219,367 shares of the biopharmaceutical company'sMarch 19, 2025 | marketbeat.comBank of New York Mellon Corp Grows Holdings in MannKind Co. (NASDAQ:MNKD)Bank of New York Mellon Corp raised its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 789,760 shares of the biopharmaceuticalMarch 18, 2025 | marketbeat.comMannKind Target of Unusually High Options Trading (NASDAQ:MNKD)MannKind Co. (NASDAQ:MNKD - Get Free Report) was the target of some unusual options trading activity on Thursday. Investors acquired 3,211 call options on the stock. This is an increase of approximately 63% compared to the typical volume of 1,971 call options.March 14, 2025 | marketbeat.comMannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025March 10, 2025 | quiverquant.comMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22March 10, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Upgraded by StockNews.com to Buy RatingStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Friday.March 7, 2025 | marketbeat.comCarrera Capital Advisors Takes $1.02 Million Position in MannKind Co. (NASDAQ:MNKD)Carrera Capital Advisors purchased a new position in MannKind Co. (NASDAQ:MNKD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 159,165 shares of the biopharmaceutical company's stock,March 5, 2025 | marketbeat.comMannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 1, 2025 | uk.finance.yahoo.comCantor Fitzgerald Raises Earnings Estimates for MannKindMannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for MannKind in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical coMarch 1, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for MannKind (NASDAQ:MNKD)Wedbush restated an "outperform" rating and set a $11.00 target price on shares of MannKind in a research note on Thursday.February 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Raised to Buy at StockNews.comStockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday.February 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Announces Quarterly Earnings ResultsMannKind (NASDAQ:MNKD - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.February 27, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD)February 27, 2025 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Stock Price Down 6.1% - Should You Sell?MannKind (NASDAQ:MNKD) Stock Price Down 6.1% - Time to Sell?February 27, 2025 | marketbeat.comMannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In QuestionFebruary 27, 2025 | seekingalpha.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼1.360.73▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼74▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News BioCryst Pharmaceuticals News Celldex Therapeutics News Dynavax Technologies News Innoviva News Novavax News OPKO Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNKD Stock Free MNKD Stock Alerts